Increasing Periarticular Injection Use in Total Joint Arthroplasties



Emily Krueger DNP, RN, AGCNS – BC, CNOR | Adam Choryan, BSN, RN | Trinity Health, Grand Rapids, MI

Background

ERAS guidelines:

- 60ml of 0.25% bupivacaine with epinephrine 1:200,000 for all total joint arthroplasties
- 15-30mg ketorolac added to local injection for total knee arthroplasties (TKA).

Goal:

- Surgeon identified goal of 100% overall compliance with periarticular injection (PAI)
- Increase ketorolac for TKAs by 50%.

Barriers identified at interdisciplinary kickoff:


- Lack of guidance for appropriate dosage of ketorolac for surgeons.
- Assumption to avoid ketorolac in all elderly patients.
- Intraoperative nurses unaware of ERAS guidelines.
- Preference card medications not standardized.


Methods

- Dosing guidelines created based on research done by dedicated surgical pharmacists. (Fig 1)
- Multiple Plan Do Study Act (PDSA) iterations undertaken over the project timeline. (Fig 2)

Renal Function and Weight	Ketorolac Dose
Calculated GFR ≥ 50 ml/min & Body Weight ≥50 kg	30mg
Calculated GFR 10-50 ml/min or Body Weight <50 kg	15mg
Calculated GFR < 10 ml/min	Avoid use

Fig 1: Pharmacy guidelines for Ketorolac dosing based on calculated glomerular filtration rate (GFR) and body weight





- Increased PAI compliance from 60% to 100%.
- Increased Ketorolac usage from 30% to over
- required by patients in all perioperative phases of care began to normalize after standardizing

- Increased education on medication practice
- Leadership support of nurses to advocate for patient care increased quality outcomes.

References